Skip to content

SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation) Study

SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation)Study for the Treatment of Chronic Low Back and Leg Pain

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01990287
Acronym
SENSE
Enrollment
38
Registered
2013-11-21
Start date
2013-11-30
Completion date
2016-02-29
Last updated
2016-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Failed Back Surgery Syndrome, Low Back Pain, Post-Laminectomy Syndrome

Keywords

Low Back Pain, Failed Back surgery Syndrome, Post-Laminectomy Syndrome, Spinal Cord Stimulation, Peripheral Nerve field Stimulation, Pain

Brief summary

The purpose of the study is to demonstrate safety and efficacy of spinal cord stimulation with peripheral nerve field stimulation for the treatment of chronic low back and leg pain.

Interventions

DEVICESCS and PNfS

Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.

DEVICESCS Alone

Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.

Sponsors

Abbott Medical Devices
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * Subject is 22 years of age or older * Subject has chronic low back and leg pain secondary to Failed Back Surgery Syndrome (FBSS) * Subject has an average score of 6 or higher for average daily overall pain on the Numerical Rating Scale (NRS) based on the 7 day pain diary * Subject has attempted best medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to physical therapy, acupuncture, etc.) and has failed medication treatment from at least two different classes * Subject's pain-related medication regimen is stable 4 weeks prior to the baseline evaluation * Subject agrees not to add or increase pain-related medication throughout the 12 week randomized evaluation phase of the study (starting at activation) Key

Exclusion criteria

* Subject currently participating in a clinical investigation that includes an active treatment arm * Subject has been implanted with a previous neuromodulation system (PNfS, SCS-PNfS or SCS) or participated in a trial for a neuromodulation system * Subject's overall Beck Depression Inventory II Score is \> 24 or has a score of 3 on question 9 relating to suicidal thoughts or wishes at the baseline visit * Subject with an infusion pump or any implantable neurostimulator device * Subject has an existing medical condition that is likely to require repetitive MRI evaluation in the future (i.e. epilepsy, stroke, multiple sclerosis, acoustic neuroma, tumor) * Subject has an existing medical condition that is likely to require the use of diathermy in the future * Subject has peripheral vascular disease * Subject is immunocompromised * Subject has documented history of allergic response to titanium or silicone * Subject has a documented history of substance abuse (narcotics, alcohol, etc.) or substance dependency in the 6 months prior to baseline data collection * Female candidates of child bearing potential that are pregnant (confirmed by positive pregnancy test)

Design outcomes

Primary

MeasureTime frameDescription
Safety6 monthsEvaluation of device or procedure related adverse events
Efficacy3 monthsResponder rate in SCS-PNfS vs SCS alone

Secondary

MeasureTime frame
Quality of Life3 months
Functional Disability3 months
Worst pain3 months
Rescue medication usage3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026